Tagged with R

Canada John London, CEO at Nuvo Pharmaceuticals Inc., explains how he and his partners turned the Canadian company from insolvency into a profitable enterprise with FDA approved products that are being marketed around the world. He further talks opportunities in the topical pain management market and how Nuvo Pharmaceuticals will enhance…

Brazil Sameer Savkur, country manager of Biogen Brazil, provides insights into the key specificities of the Brazilian pharmaceutical ecosystem and documents the great successes of Biogen affiliate in working hand-in-hand with all key public and regulatory stakeholders in Brazil, as recently illustrated with Biogen’s innovative treatment for spinal muscular atrophy (SMA),…

Austria Joy Ladurner, co-director of the NKSE (National Coordination Center for Rare Diseases) in Austria, discusses the rationale behind Austria’s prioritization of rare diseases and its leading role in the field. Austria launched a national action plan for rare diseases, the NAP.se in 2015. NKSE has played an instrumental role in…

Switzerland In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new CAR-T cell therapy, Kymriah, and the issues around pricing for this revolutionary treatment.   * Please note that this interview was…

Serbia Vera Nikolic-Dimic, executive director of the American Chamber of Commerce (AmCham) in Serbia, pinpoints the key facets of the Serbian economy that have captivated the interests of American businesses, the challenges and opportunities companies operating in the country are currently facing, as well as the Chamber’s fundamental role in promoting…

Brazil Dr. Florentino Cardoso, president of the Brazilian Medical Association, discusses the challenges of navigating Brazil’s healthcare system and reveals his aim to promote the needs of the medical community to ultimately ensure the best patient outcomes. Can you describe your background and introduce yourself to our executive readership? “As for…

India “From illness to wellness” – this is what Apollo Life is all about. Ariz Rizvi, president of Apollo Life, gives his insight into the current state of occupational and rehabilitative health in India and explains how the company has revolutionized wellness in workplaces over the past years. Mr. Rizvi, you…

Brazil Henrique Tada, executive director of ALANAC, the association gathering Brazilian pharmaceutical companies, provides an historical overview of the rapid and eye-catching growth of the local pharmaceutical industry and documents the new development opportunities envisioned by domestic manufacturers with regards to botanical and biological drugs as well as their competitive advantages…

Canada Brian Lewis, president and CEO of MEDEC, speaks towards the importance of building a strong medical device ecosystem and the association’s collaboration with industry stakeholders to push advancements in terms of value-based healthcare to not only improve the overall quality of patient care but also to ultimately support the sustainability…

Austria Alexander Biach, chairman of the Main Association of Austrian Social Security Institutions, discusses handling the responsibility for Austria’s Europe-leading social security coverage, current inefficiencies that need to be ironed out, and his blueprint for creating a faster, less complicated, more cost-effective, and equitable social insurance system. Last May, you were…

Brazil Luis Eduardo Caroli, CEO of BioZeus, is contributing to the pre-commercial development of Brazilian-born innovations. In this interview he explains how he set up the company and documents the company’s unique model of collaboration between local project managers and highly experienced senior international executives to develop academic science, as well…

Serbia Bojan Trkulja, managing director of INOVIA, Serbia’s innovative drug manufacturers association, underlines the importance of cooperation not only between his members but also between all the key stakeholders of the Serbian healthcare and life science industry, concluding that the time for investment in Serbia is now and that the country…